Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

OBJECTIVE: To evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic. METHODS: In our retrospective, multicenter cohort study, we compared patients with RRMS on EID (...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolfes, Leoni, Pawlitzki, Marc, Pfeuffer, Steffen, Nelke, Christopher, Lux, Anke, Pul, Refik, Kleinschnitz, Christoph, Kleinschnitz, Konstanze, Rogall, Rebeca, Pape, Katrin, Bittner, Stefan, Zipp, Frauke, Warnke, Clemens, Goereci, Yasemin, Schroeter, Michael, Ingwersen, Jens, Aktas, Orhan, Klotz, Luisa, Ruck, Tobias, Wiendl, Heinz, Meuth, Sven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362352/
https://www.ncbi.nlm.nih.gov/pubmed/34261812
http://dx.doi.org/10.1212/NXI.0000000000001035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362352/
https://www.ncbi.nlm.nih.gov/pubmed/34261812
http://dx.doi.org/10.1212/NXI.0000000000001035

Ejemplares similares